{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:04:36Z","timestamp":1789167876004,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01 CA131274"],"award-info":[{"award-number":["R01 CA131274"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01 ES011740"],"award-info":[{"award-number":["R01 ES011740"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.lungcan.2010.10.011","type":"journal-article","created":{"date-parts":[[2010,11,14]],"date-time":"2010-11-14T04:16:53Z","timestamp":1289708213000},"page":"370-377","source":"Crossref","is-referenced-by-count":40,"title":["No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: A meta-analysis"],"prefix":"10.1016","volume":"72","author":[{"given":"Ming","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingrong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Voutsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Tibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Christiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca S.","family":"Heist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Rosell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Booton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2010.10.011_bib0005","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1054\/bjoc.2000.1740","article-title":"Meta-analysis of single agents in the chemotherapy of NSCLC: what do we want to know?","volume":"84","author":"Bahl","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0010","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/00001813-199308000-00011","article-title":"Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines","volume":"4","author":"Shellard","year":"1993","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0015","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/01.fpc.0000239975.77088.17","article-title":"Tagging single nucleotide polymorphisms in excision repair cross-complementing group 1 (ERCC1) and risk of primary lung cancer in a Chinese population","volume":"17","author":"Ma","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0020","first-page":"555","article-title":"Comparison of two human ovarian carcinoma cell lines (A2780\/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene","volume":"16","author":"Yu","year":"2000","journal-title":"Int J Oncol"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0025","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/carcin\/21.5.965","article-title":"Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells","volume":"21","author":"Duell","year":"2000","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0030","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/carcin\/21.4.551","article-title":"XPD polymorphisms: effects on DNA repair proficiency","volume":"21","author":"Lunn","year":"2000","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0035","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.lungcan.2008.08.006","article-title":"Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature","volume":"64","author":"Vilmar","year":"2009","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0040","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdh319","article-title":"Single nucleotide polymorphisms and outcome in docetaxel\u2013cisplatin-treated advanced non-small-cell lung cancer","volume":"15","author":"Isla","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0045","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1158\/1078-0432.CCR-07-1364","article-title":"Correlation of CDA ERCC1, and XPD polymorphisms with response and survival in gemcitabine\/cisplatin-treated advanced non-small cell lung cancer patients","volume":"14","author":"Tibaldi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0050","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0055","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0060","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0065","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/gepi.20435","article-title":"Meta-analysis of genome-wide association studies: no efficiency gain in using individual participant data","volume":"34","author":"Lin","year":"2009","journal-title":"Genet Epidemiol"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0070","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1097\/01243894-200611000-00009","article-title":"A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report","volume":"1","author":"Pillot","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0075","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1200\/JCO.2008.20.8793","article-title":"Japanese\u2013US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics","volume":"27","author":"Gandara","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0080","first-page":"4899","article-title":"Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells","volume":"62","author":"Furuta","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0085","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/jnci\/94.14.1091","article-title":"An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer","volume":"94","author":"Bosken","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0090","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0027-5107(02)00219-1","article-title":"Rapid assessment of repair of ultraviolet DNA damage with a modified host-cell reactivation assay using a luciferase reporter gene and correlation with polymorphisms of DNA repair genes in normal human lymphocytes","volume":"509","author":"Qiao","year":"2002","journal-title":"Mutat Res"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0095","first-page":"1354","article-title":"Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients","volume":"61","author":"Spitz","year":"2001","journal-title":"Cancer Res"},{"issue":"February","key":"10.1016\/j.lungcan.2010.10.011_bib0100","article-title":"Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis","author":"Wei","year":"2010","journal-title":"Med Oncol"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0105","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3816\/CLC.2009.n.015","article-title":"DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer","volume":"10","author":"Kalikaki","year":"2009","journal-title":"Clin Lung Cancer"},{"issue":"March","key":"10.1016\/j.lungcan.2010.10.011_bib0110","article-title":"Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer","author":"Li","year":"2010","journal-title":"Am J Clin Oncol"},{"issue":"June","key":"10.1016\/j.lungcan.2010.10.011_bib0115","article-title":"The platinum-based treatments for advanced non-small cell lung cancer, is low\/negative ERCC1 expression better than high\/positive ERCC1 expression? A meta-analysis","author":"Chen","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0921-8777(99)00022-1","article-title":"Adaptive enhancement and kinetics of nucleotide excision repair in humans","volume":"435","author":"Ye","year":"1999","journal-title":"Mutat Res"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0125","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1002\/cncr.21885","article-title":"Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer","volume":"106","author":"Booton","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0130","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3816\/CLC.2003.n.004","article-title":"Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine\/cisplatin-treated advanced non-small-cell lung cancer patients","volume":"4","author":"Camps","year":"2003","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0135","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.lungcan.2003.11.019","article-title":"Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy","volume":"44","author":"Ryu","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0140","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.lungcan.2006.12.002","article-title":"Genetic polymorphisms and treatment response in advanced non-small cell lung cancer","volume":"56","author":"Su","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0145","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1158\/1078-0432.CCR-04-0247","article-title":"Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy","volume":"10","author":"Zhou","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0150","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1385\/MO:23:4:489","article-title":"Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients","volume":"23","author":"Park","year":"2006","journal-title":"Med Oncol"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0155","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/annonc\/mdj135","article-title":"Polymorphisms in DNA repair genes modulate survival in cisplatin\/gemcitabine-treated non-small-cell lung cancer patients","volume":"17","author":"de las Penas","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0160","article-title":"Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer","author":"Okuda","year":"2009","journal-title":"J Surg Res"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0165","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ijheh.2010.01.004","article-title":"Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients","volume":"213","author":"Chen","year":"2010","journal-title":"Int J Hyg Environ Health"},{"issue":"May","key":"10.1016\/j.lungcan.2010.10.011_bib0170","article-title":"Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients","author":"Zhou","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0175","first-page":"859","article-title":"Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers","volume":"10","author":"Yao","year":"2009","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.lungcan.2010.10.011_bib0180","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.2004.08.067","article-title":"XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy","volume":"22","author":"Gurubhagavatula","year":"2004","journal-title":"J Clin Oncol"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500210005167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500210005167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T02:46:55Z","timestamp":1711939615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500210005167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0169500210005167"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2010.10.011","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}